| Date | Title | Description |
| 07.05.2024 | Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential | CUREator by Brandon BioCatalyst has announced the deployment of $7.21 million in funding to support eight biotech companies across their Clinical and Preclinical streams thanks to the Federal Government’s Medical Research Future Fund’s Earl... |
| 30.04.2024 | ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator | Melbourne, Australia, 29 April 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, anno... |
| 30.04.2024 | Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic | Fundraising Includes New Strategic Investment by Bristol Myers Squibb along with Continued Support from Existing Investors including Canaan and Brandon Capital
Proceeds to be Used to Advance Lead Candidate, PTT-4256, into the Clinic and Exp... |
| 18.04.2024 | Fundraising Includes New Strategic Investment by Bristol Myers Squibb along with Continued Support from Existing Investors including Canaan and Brandon Capital | Proceeds to be Used to Advance Lead Candidate, PTT-4256, into the Clinic and Expand Leadership Team to Align with Pathios’ Transition into a Clinical-Stage Company
OXFORD, UK – April 18, 2024 – Pathios Therapeutics Limited (“Pathios”), a bi... |
| 02.04.2024 | Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases | —Azura to present 10 abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) and the Association for Research in Vision and Ophthalmology (ARVO), showcasing a breadth of data supporting the potential for a new therapeut... |
| 15.02.2024 | Brandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator | Brandon BioCatalyst’s CUREator, in partnership with ANDHealth, is set to deliver a BioMedTech Incubator (BMTI) focused on developing research discoveries and medical innovations with commercial potential to address dementia and cognitive de... |
| 23.01.2024 | 23 Jan 2024: Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy | Aravax, a clinical stage biotechnology company developing the first rationally designed and precisely targeted immunotherapeutic for peanut allergy (PVX108), today announces it has closed its Series B funding round with a total of US$42.2m.... |
| 06.12.2023 | CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023 | Munich, Germany, December 6, 2023 – CatalYm announced that maturing Phase 2a results from its ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) were presented today in an oral presentat... |
| 27.11.2023 | Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies | Scientists Uncover Central Role of N-Myristoylation in Senescence |
| 26.11.2023 | Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Ga... | CAMBRIDGE, Mass. & BRISBANE, Australia-Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has published positive results from a human clinical trial involving its potentially game-changing techn... |
| 16.11.2023 | Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma | Melbourne, Australia: 16 November 2023 – Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, announces the presentation of results of its Phase ... |
| 15.11.2023 | Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors | London, UK 15 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), toda... |
| 02.11.2023 | PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery,biodegradable ocular implant in glaucoma patients. | Melbourne, 1st November 2023: PolyActiva is a Melbourne-based ophthalmology company developing a novel proprietary drug delivery platform. Today the company reported promising interim results from an ongoing Phase 2a clinical study for its ... |
| 19.10.2023 | Myricx Bio Wins Best Poster at World ADC | London, UK, 19 October 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has won the awar... |
| 09.10.2023 | - | Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease |
| 27.09.2023 | Recruitment completes for second Phase III hypertension trial investigating GMRx2 | George Medicines completes recruitment of second Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2
– More than 250 patients enrolled in placebo-controlled trial evaluating efficacy and safety of... |
| 27.09.2023 | Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer | Company Collaborating with Researchers at the University of Nottingham on Optimization and Evaluation of Novel Small Molecule GPR65 Inhibitors in Preclinical Brain Tumor Models |
| 11.09.2023 | New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance | Melbourne, Australia and Milan, Italy, 11 September 2023 – ENA Respiratory, a clinical-stage pharmaceutical company, announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunom... |
| 05.09.2023 | Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer | BOSTON-Glyscend Therapeutics, a clinical-stage biopharmaceutical company that is reshaping the treatment of metabolic disease, including obesity and type 2 diabetes, with first-in-class oral polymer medicines that address unmet needs for pa... |
| 27.08.2023 | Dr. Yuri Maricich joins PKG Health as its Chief Medical & Scientific Officer | PKG Health is pleased to announce that Dr. Yuri Maricich has joined the leadership team as Chief Medical & Scientific Officer. |
| 23.08.2023 | VAXXAS AWARDED US$3.67 MILLION (AU$5.4 MILLION) FROM GLOBAL CHARITABLE FOUNDATION, WELLCOME, FOR HUMAN CLINICAL STUDY OF TYPHOID VACCINATION USING NEEDLE-FREE VACCINE PATCH | Cambridge, Mass., USA, and Brisbane, Queensland, Australia – August 23, 2023 – Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that the global charitable foundation, Wellcome, has... |
| 15.08.2023 | CUREator+ delivers $50m funding boost to commercially focused BioMedTech startups | Expressions of Interest for CUREator+, a newly created $50 million program by Brandon BioCatalyst and ANDHealth, are now open. |
| 03.08.2023 | Cicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst | Australia’s flagship deep tech incubator Cicada Innovations is expanding with the opening of a health-focused incubator at one of Australia’s largest health and biomedical research precincts, the Westmead Health and Innovation District, and... |
| 18.07.2023 | State Government Backs OncoRes Medical with Funding to Manufacture Digital Cancer ImagingDevice in WA | Perth, 18/07/2023 – OncoRes Medical, a Perth-based medical device company, has secured $3M grant funding from the Cook Government’s Department of Jobs, Tourism, Science, and Innovation, further bolstering their successful financial year.... |
| 06.06.2023 | Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform technology, today announced the appointment of Dr. Rochelle Chaiken, as Chief Medical Officer. Dr. Chaiken joins Vaxxas following a 23-year career a... |
| 06.06.2023 | Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ p... |
| 02.06.2023 | Aravax doses first patient in Phase 2 peanut allergy clinical trials | The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted unde... |
| 02.06.2023 | Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity | BOSTON–(BUSINESS WIRE)–Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies, today announced clinical progress with its lead candidate... |
| 24.05.2023 | Nineteen groundbreaking biotech projects selected for national incubator | CUREator, Australia’s national biotech incubator, today announces its second round of funding, awarding $12 million to 19 projects targeting global health challenges including advances in treatment for lupus, motor neurone disease, brain an... |
| 22.05.2023 | EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation | Melbourne, 22 May 2023 – EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchroniz... |
| 22.05.2023 | EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation | EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) Syste... |
| 03.05.2023 | Healthcare Veteran, Zach Henderson to lead Global Kinetics as CEO | Charlotte, US & Melbourne, Australia – May 3, 2023, Global Kinetics, the global leader in digital health solutions for neurological conditions, today announced the appointment of Zach Henderson as its new Chief Executive Officer. Zach w... |
| 21.03.2023 | Brandon BioCatalyst, in partnership with ANDHealth, selected by the Federal Government to deliver $50m BioMedTech Incubator Program | Federal investment creates a combined funding capability of $115m across programs managed by Brandon BioCatalyst & ANDHealth. |
| 10.03.2023 | Aravax initiates Phase 2 peanut allergy clinical trials in Australia | Aravax, a clinical stage biotechnology company developing next generation immunotherapies which are safe, convenient, and precisely targeted, today announces it has initiated the first clinical trial sites in Australia for AVX-201 in Austra... |
| 09.03.2023 | Tech entrepreneur amongst stellar cohort in latest Women in Leadership Development (WILD) Program, which is expanding with new Federal investment | One of Australia’s most promising tech entrepreneurs joins a stellar cohort partaking in this year’s Women in Leadership Development (WILD) Program, which starts in Melbourne this week. |
| 14.02.2023 | Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study | ENA Respiratory, a clinical-stage pharmaceutical company, announced that INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of respiratory viral infections, was found to significantly impac... |
| 10.02.2023 | Vaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP) | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate deli... |
| 06.02.2023 | Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients | Certa Therapeutics (Certa) today announces ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. |
| 19.01.2023 | Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access | CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas , a clinical-stage biotechnology company commercializing a novel vaccination platform, have signed a partnership agreement to advance the development of Vaxxas’ needle-fr... |
| 10.01.2023 | ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051 | Clinical-stage pharmaceutical company ENA Respiratory has been awarded a $4.38 million USD agreement from the U.S. Department of Defense (DoD) to support ongoing research and development of INNA-051, a clinical stage first-in-class broadspe... |
| 20.12.2022 | Aravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile | Aravax, a clinical stage biotechnology company developing the first safe, convenient, and precisely targeted immunotherapeutic for peanut allergy (PVX108), today announces it has commenced its series B funding round with an investment of US... |
| 20.12.2022 | Billionaires Andrew and Nicola Forrest take aim at peanut allergy | Billionaires Andrew and Nicola Forrest are taking aim at peanut allergy with their new healthcare venture, backing a small biotech looking to develop the first safe, convenient, and targeted treatment for the common allergen. |
| 06.12.2022 | Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement | Entact Bio, the company pioneering the development of precision medicines that enhance the function of key proteins, today announced it has raised $81 million in Series A financing to advance its proprietary Encompass™ platform for developi... |
| 06.12.2022 | Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate | Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced it has completed a financing round which raised US$23 million (A$34 million) in new funds. This investment round was led by existin... |
| 22.11.2022 | CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors | CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Nov... |
| 17.11.2022 | Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction | – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced positive 3-month efficacy and safety results from its Phase 2b s... |
| 11.11.2022 | QUE Oncology’s non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer, published in The Lancet | QUE Oncology announces the results of its Phase II trial of Q-122, a novel non-hormonal oral therapy for the treatment of vasomotor symptoms (commonly known as hot flashes/flushes and night sweats) in women taking endocrine therapy for brea... |
| 09.11.2022 | Brandon Capital Invests in Neuroscience Company NRG Therapeutics | Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its investment into neuroscience company NRG Therapeutics as part of its £16m (AUD$29m) series A financing. |
| 09.11.2022 | Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP) | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietar... |
| 09.11.2022 | First Aussies to get needle-free COVID-19 vaccine patch | - |
| 04.11.2022 | Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022 | - |
| 04.11.2022 | Certa Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases | Certa Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases |
| 02.11.2022 | First in-human use of OncoRes Medical’s cancer imaging technology successful | Quantitative Micro-Elastography (QME) Imaging System published in peer reviewed Cancer Research |
| 20.10.2022 | Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents | Supports continued advancement of first-in-class Ophthalmic Keratolytics for ocular surface diseases |
| 12.10.2022 | Opinion: Taking the leap: transitioning from academia to industry – by Christina Kulis | Leaving academia is rarely a simple decision, no matter what career stage you are at or where you are headed next. Change is not always easy. Researchers looking to transition into industry are often faced with some uncertainty, but also lo... |
| 28.09.2022 | Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics | Melbourne, Australia and London UK, 28 September 2022 –Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its leading role in the USD68m series A financing of Pheon Therapeutics (Pheon), that ha... |
| 21.09.2022 | Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment | Glyscend Therapeutics, a clinical-stage biotechnology company, today reported additional biomarker results from their Phase 1 study of GLY-200, a proprietary orally administered, gut-restricted therapeutic for the treatment of type 2 diabet... |
| 21.09.2022 | Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB) | SAB comprised of leading experts in ophthalmology to provide strategic support for the advancement of Azura’s first-in-class Ophthalmic Keratolytics |
| 15.09.2022 | Medisanté and George Medicines collaborate to bring Internet of Things (IoT) data collection to decentralised Phase III trial of single-pill triple combination candidate to treat hypertension | • Remote cellular-enabled blood pressure monitoring provides novel and secure way of collecting real world data (RWD) in decentralised global phase III pivotal study
• Unique remote device monitoring (RDM) capabilities of Medisanté’s medica... |
| 08.09.2022 | George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial | George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announced that its novel single-pill, triple combination candidate, GMRx2, is be... |
| 05.09.2022 | $16m cash injection to progress first-in-class therapy for inflammation and fibrosis | Australian start-up OccuRx accelerates therapy development for diseases associated with inflammation and fibrosis – the cause of 45% of all deaths globally1 |
| 28.08.2022 | Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction | Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the c... |
| 17.08.2022 | Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort | Funding awarded by Brandon BioCatalyst’s CUREator |
| 27.07.2022 | Vaxxas patch worked for all Covid strains | A protein-based vaccine patch has proved effective against all major variants of Covid when given to mice, say researchers. |
| 20.07.2022 | Australia’s first national biotech incubator announces round one funding to support life science breakthroughs | Melbourne, 20 July 2022: Australia’s national biotech incubator, CUREator today announces it is providing $17.4 million to projects aiming to tackle global health concerns including diabetes, cardiovascular disease and cancer. The incubator... |
| 19.07.2022 | CUREator, the national biotechnology incubator, backs 23 start ups | The government-backed national biotechnology incubator has made its first round of grants, worth $17.4m, to start-up companies around the nation tackling health problems such as diabetes, cardiovascular disease and cancer. |
| 05.07.2022 | CSIRO and Australian incubator CUREator boost health security innovation | $3m additional funding provided by CSIRO to CUREator, Australia’s national biotech incubator, to boost home-grown health security discoveries, taking total incubation capital to $43m |
| 09.06.2022 | Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board | Promising ‘dark matter’ cancer therapy has clinical trials in sight |
| 06.06.2022 | Over $15m invested in world-leading cancer immunotherapy | University of Auckland spinout targeting new cancer treatment |
| 31.05.2022 | Vaxxas and University of Sydney complete study assessing needle-free HD-MAP technology for vaccine administration | Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of ... |
| 18.05.2022 | Australian medical device company secures additional $12.5m to advance its breast cancer imaging system towards clinical trials | OncoRes Medical’s imaging system may be a game-changer for breast cancer surgeons |
| 12.05.2022 | ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected... |
| 12.05.2022 | Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment | Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies for metabolic and chronic conditions, today reported the completion of a Phase 1 trial for its lead clinical-... |
| 10.05.2022 | Opinion: Aduhelm – Providing hope to millions of Alzheimer’s Disease patients worldwide? – Katherine Jackman | When I first heard the news that the FDA had approved Aduhelm – Biogen’s anti-amyloid β, disease modifying therapy for Alzheimer’s disease (AD) – I was excited. I had followed the review process closely and had anticipated a ”no” from the F... |
| 06.05.2022 | Aravax appoints Dr Brett Haumann to Board of Directors | Aravax, a clinical stage biotechnology company focused on developing the most advanced novel therapy for peanut allergy, which is designed to be safe, effective, and convenient, today announces the appointment of industry executive Dr Brett... |
| 03.05.2022 | Australian collaboration and AU$10m investment fuels Ankere Therapeutics’ efforts to target inflammatory lung conditions | Australian biotech company, Ankere Therapeutics (‘Ankere’), has launched with AU$10 million seed investment to develop new therapies which target inflammatory diseases, particularly those affecting the lung. |
| 28.04.2022 | AIC growth private equity awards: Allegro Funds, Brandon Capital clean out | Australian Investment Council belatedly held its 2021 awards for growth private equity firms on Thursday evening in Sydney, and Allegro Funds’ team must’ve come back from the party grinning ear to ear. |
| 18.04.2022 | Parkinson’s patients benefit from revolutionary watch on the NHS to manage care at home | Patients with Parkinson’s disease are being given life-changing smart watches that allow doctors to remotely assess their condition in a pioneering project to revolutionise NHS care. |
| 12.04.2022 | Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at... | Human ex vivo data demonstrate the promise of Pathios’ ‘Macrophage Conditioning’ approach in reversing the immunosuppressive polarization of macrophages brought about by an acidic microenvironment |
| 04.04.2022 | Boosting product confidence of a world-leading RNA therapeutics start-up | CSIRO’s Transformational Bioinformatics group validates the importance of long non-coding RNAs (lncRNAs) as novel cancer therapeutics targets. |
| 24.03.2022 | Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches | Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that The University of Texas at Austin has granted Vaxxas an exclusive license to a next-gen... |
| 16.03.2022 | First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of ... |
| 09.03.2022 | Medical Research Commercialisation Fund (MRCF) renamed Brandon BioCatalyst | The Medical Research Commercialisation Fund (MRCF), Australia and New Zealand’s largest life science investment collaboration, has been renamed Brandon BioCatalyst. |
| 04.03.2022 | Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy | Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut allergy which is designed to be safe, effective and convenient, today announces that it has received a green light for its Investigational New... |
| 23.02.2022 | ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19 in pop... |
| 18.02.2022 | PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology | - |
| 17.01.2022 | Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill | George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announced that its proprietary triple low-dose combination pill, GMRx2, will be ... |
| 30.11.2021 | Q-Sera enters exclusive agreement with Terumo Corporation for RAPClot™ rapid serum blood collection tube technology in Japan | Q-Sera Pty Ltd, an Australian venture-backed company, today announced a partnership with Terumo Corporation, the leading Japanese medical device company, which will see its patent protected RAPClot™ rapid serum tube technology manufactured ... |
| 27.11.2021 | Healthy Outlook: Where your super is invested | A nasal spray to prevent Covid-19, a pill to put Type 2 diabetes into remission and a wireless pacemaker are among the game-changing clinical trials funded through superannuation contributions |
| 24.11.2021 | Silicon Valley pacemaker hopes to capture Aussie hearts with ASX float | Silicon Valley pacemaker startup EBR Systems expects Australia’s strong research focus on heart disease will be a fertile environment to develop the products it hopes will solve one of the world’s biggest global health problems. |
| 19.11.2021 | Hard WA border a boon for life sciences sector | WA’s tough border stance might make it difficult to find employees in many industries but for the State’s burgeoning life sciences sector, it’s had the opposite effect. |
| 11.11.2021 | Life science researchers and entrepreneurs encouraged to seek investment from new $40m Australian biotech incubator | Australian biotech researchers and entrepreneurs are being encouraged to apply for funding from Australia’s first national biotech incubator, CUREator, established with $40m funding from the Federal Government’s Medical Research Future Fund... |
| 29.09.2021 | Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Ther... | Phase 1 clinical trial currently underway in Australia investigating a noninvasive, oral polymer therapy that dramatically improves glucose homeostasis with weight loss in nonclinical models. |
| 28.09.2021 | First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials | — ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost innate immunity |
| 23.09.2021 | Drug repurposing is no panacea in race to treat COVID-19 | Drug repurposing is no quick fix for developing new treatments for disease, including COVID-19, and there are inherent dangers and pitfalls with translating drugs such as chloroquine, hydroxychloroquine, ivermectin and similar compounds to ... |
| 16.09.2021 | Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform | Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of its oversubscribed $60M Series C financi... |
| 15.09.2021 | Hope offered to Australians suffering from a rare incurable fibrotic autoimmune disease, as clinical trials on new treatment commence | A new treatment for Diffuse Systemic Scleroderma, a debilitating chronic autoimmune disease that affects 6,000 Australians and has no cure, has begun Phase II trials in Australia. |
| 07.09.2021 | Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler, M.D. as Chair of the Board | Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian Gland Dysfunction (MGD) and related eye diseases, today announced the appointment of Steven M. Altschuler, M.D., as chair of its board of directo... |
| 23.08.2021 | Australia’s first national biotech incubator established with $40m MRFF investment | Australia’s first national biotech incubator is to be established with $40m funding from the Federal Government’s Medical Research Future Fund (MRFF) and will be run by the Brandon Capital-managed Medical Research Commercialisation Fund (MR... |
| 23.08.2021 | ‘New dawn’ for biotech with taxpayer-funded incubator | The pandemic is steering the venture capital lens away from shorter-term sugar hits found in the technology sector in a “new dawn” for the local life science and biotech fields, one of Australia’s pioneering investors says. |